Chapter 41. Diffuse Large B-Cell Lymphoma

  1. Mark A. Crowther MD, MSc, FRCPC Professor Division Director2,3,
  2. Jeff Ginsberg MD, FRCPC Professor4,
  3. Holger J. Schünemann MD, PhD, MSc, FACP, FCCP Professor5,6,
  4. Ralph M. Meyer MD, FRCPC Director Professor7,8 and
  5. Richard Lottenberg MD, FACP Professor9
  1. Michael Crump MD, FRCPC

Published Online: 4 FEB 2009

DOI: 10.1002/9781444300857.ch41

Evidence-Based Hematology

Evidence-Based Hematology

How to Cite

Crump, M. (2008) Diffuse Large B-Cell Lymphoma, in Evidence-Based Hematology (eds M. A. Crowther, J. Ginsberg, H. J. Schünemann, R. M. Meyer and R. Lottenberg), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444300857.ch41

Editor Information

  1. 2

    Division of Hematology, McMaster University, Hamilton, Ontario, Canada

  2. 3

    St. Joseph's Hospital, Hamilton, Ontario, Canada

  3. 4

    Department of Medicine, McMaster University, Hamilton, Canada

  4. 5

    CLARITY Research Group, Department of Epidemiology, Italian National Cancer Institute Regina Elena, Rome, Italy

  5. 6

    McMaster University, Hamilton, Canada

  6. 7

    National Cancer Institute of Canada, Clinical Trials Group, Edith Eisenhauer Chair in Clinical Cancer Research, Queen's University, Kingston, Ontario, Canada

  7. 8

    Departments of Oncology and Medicine, Queen's University, Kingston, Ontario, Canada

  8. 9

    Division of Hematology/Oncology, Department of Medicine, University of Florida College of Medicine, Gainesville, Florida, USA

Author Information

  1. Princess Margaret Hospital, Division of Medical Oncology and Hematology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada

Publication History

  1. Published Online: 4 FEB 2009
  2. Published Print: 27 JUN 2008

ISBN Information

Print ISBN: 9781405157476

Online ISBN: 9781444300857



  • Diffuse large B-cell lymphoma (DLBCL);
  • literature-search strategy and inclusion;
  • patients with localized stages I and II DLBCL;
  • rituximab with second-line chemotherapy prior to autologous transplantation for patients;
  • advanced DLBCL and dose-dense chemotherapy supported by growth factors;
  • Dutch-Belgium Group, HOVON;
  • intensification of therapy using G-CS;
  • DLBCL adult patients and CHOP chemotherapy with curative intent


This chapter contains sections titled:

  • Introduction

  • Questions

  • Literature-search strategy and inclusion

  • Should patients with DLBCL receive involved-field radiation as part of primary therapy?

  • Should patients with a good response to chemotherapy who are at high risk for recurrence receive consolidation with autologous stem cell transplantation?

  • Should rituximab be added to second-line therapy for patients with relapsed disease?

  • Should patients with advanced DLBCL receive dose-dense chemotherapy supported by growth factors?

  • Should older patients with DLBCL receive CHOP chemotherapy with curative intent?

  • References